218 related articles for article (PubMed ID: 31945318)
1. ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma.
Persson CU; von Stedingk K; Fredlund E; Bexell D; Påhlman S; Wigerup C; Mohlin S
Exp Cell Res; 2020 Mar; 388(2):111845. PubMed ID: 31945318
[TBL] [Abstract][Full Text] [Related]
2. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
3. Marked and rapid effects of pharmacological HIF-2α antagonism on hypoxic ventilatory control.
Cheng X; Prange-Barczynska M; Fielding JW; Zhang M; Burrell AL; Lima JD; Eckardt L; Argles I; Pugh CW; Buckler KJ; Robbins PA; Hodson EJ; Bruick RK; Collinson LM; Rastinejad F; Bishop T; Ratcliffe PJ
J Clin Invest; 2020 May; 130(5):2237-2251. PubMed ID: 31999648
[TBL] [Abstract][Full Text] [Related]
4. 3-[(1
Xu R; Wang K; Rizzi JP; Huang H; Grina JA; Schlachter ST; Wang B; Wehn PM; Yang H; Dixon DD; Czerwinski RM; Du X; Ged EL; Han G; Tan H; Wong T; Xie S; Josey JA; Wallace EM
J Med Chem; 2019 Aug; 62(15):6876-6893. PubMed ID: 31282155
[TBL] [Abstract][Full Text] [Related]
5. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
[TBL] [Abstract][Full Text] [Related]
6. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Puppo M; Battaglia F; Ottaviano C; Delfino S; Ribatti D; Varesio L; Bosco MC
Mol Cancer Ther; 2008 Jul; 7(7):1974-84. PubMed ID: 18645007
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha.
Zhang H; Pu J; Qi T; Qi M; Yang C; Li S; Huang K; Zheng L; Tong Q
Oncogene; 2014 Jan; 33(3):387-97. PubMed ID: 23222716
[TBL] [Abstract][Full Text] [Related]
8. Modulation of HIF-2α PAS-B domain contributes to physiological responses.
Feng Z; Zou X; Chen Y; Wang H; Duan Y; Bruick RK
Proc Natl Acad Sci U S A; 2018 Dec; 115(52):13240-13245. PubMed ID: 30523118
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2
Xie C; Gao X; Sun D; Zhang Y; Krausz KW; Qin X; Gonzalez FJ
Drug Metab Dispos; 2018 Apr; 46(4):336-345. PubMed ID: 29363499
[TBL] [Abstract][Full Text] [Related]
10. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype.
Holmquist-Mengelbier L; Fredlund E; Löfstedt T; Noguera R; Navarro S; Nilsson H; Pietras A; Vallon-Christersson J; Borg A; Gradin K; Poellinger L; Påhlman S
Cancer Cell; 2006 Nov; 10(5):413-23. PubMed ID: 17097563
[TBL] [Abstract][Full Text] [Related]
11. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).
Wehn PM; Rizzi JP; Dixon DD; Grina JA; Schlachter ST; Wang B; Xu R; Yang H; Du X; Han G; Wang K; Cao Z; Cheng T; Czerwinski RM; Goggin BS; Huang H; Halfmann MM; Maddie MA; Morton EL; Olive SR; Tan H; Xie S; Wong T; Josey JA; Wallace EM
J Med Chem; 2018 Nov; 61(21):9691-9721. PubMed ID: 30289716
[TBL] [Abstract][Full Text] [Related]
12. HIF-2α/ARNT complex regulates hair development via induction of p21(Waf1/Cip1) and p27(Kip1).
Imamura Y; Tomita S; Imanishi M; Kihira Y; Ikeda Y; Ishizawa K; Tsuchiya K; Tamaki T
FASEB J; 2014 Jun; 28(6):2517-24. PubMed ID: 24599965
[TBL] [Abstract][Full Text] [Related]
13. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor.
Renfrow JJ; Soike MH; West JL; Ramkissoon SH; Metheny-Barlow L; Mott RT; Kittel CA; D'Agostino RB; Tatter SB; Laxton AW; Frenkel MB; Hawkins GA; Herpai D; Sanders S; Sarkaria JN; Lesser GJ; Debinski W; Strowd RE
Sci Rep; 2020 Sep; 10(1):15195. PubMed ID: 32938997
[TBL] [Abstract][Full Text] [Related]
14. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
[TBL] [Abstract][Full Text] [Related]
15. A splice variant of the human ion channel TRPM2 modulates neuroblastoma tumor growth through hypoxia-inducible factor (HIF)-1/2α.
Chen SJ; Hoffman NE; Shanmughapriya S; Bao L; Keefer K; Conrad K; Merali S; Takahashi Y; Abraham T; Hirschler-Laszkiewicz I; Wang J; Zhang XQ; Song J; Barrero C; Shi Y; Kawasawa YI; Bayerl M; Sun T; Barbour M; Wang HG; Madesh M; Cheung JY; Miller BA
J Biol Chem; 2014 Dec; 289(52):36284-302. PubMed ID: 25391657
[TBL] [Abstract][Full Text] [Related]
16. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
Martínez-Sáez O; Gajate Borau P; Alonso-Gordoa T; Molina-Cerrillo J; Grande E
Crit Rev Oncol Hematol; 2017 Mar; 111():117-123. PubMed ID: 28259286
[TBL] [Abstract][Full Text] [Related]
17. HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
Courtney KD; Ma Y; Diaz de Leon A; Christie A; Xie Z; Woolford L; Singla N; Joyce A; Hill H; Madhuranthakam AJ; Yuan Q; Xi Y; Zhang Y; Chang J; Fatunde O; Arriaga Y; Frankel AE; Kalva S; Zhang S; McKenzie T; Reig Torras O; Figlin RA; Rini BI; McKay RM; Kapur P; Wang T; Pedrosa I; Brugarolas J
Clin Cancer Res; 2020 Feb; 26(4):793-803. PubMed ID: 31727677
[TBL] [Abstract][Full Text] [Related]
18. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
Courtney KD; Infante JR; Lam ET; Figlin RA; Rini BI; Brugarolas J; Zojwalla NJ; Lowe AM; Wang K; Wallace EM; Josey JA; Choueiri TK
J Clin Oncol; 2018 Mar; 36(9):867-874. PubMed ID: 29257710
[TBL] [Abstract][Full Text] [Related]
19. Ligand-induced perturbation of the HIF-2α:ARNT dimer dynamics.
Motta S; Minici C; Corrada D; Bonati L; Pandini A
PLoS Comput Biol; 2018 Feb; 14(2):e1006021. PubMed ID: 29489822
[TBL] [Abstract][Full Text] [Related]
20. Chronic hypoxia impairs skeletal muscle repair via HIF-2α stabilization.
Yin A; Fu W; Elengickal A; Kim J; Liu Y; Bigot A; Mamchaoui K; Call JA; Yin H
J Cachexia Sarcopenia Muscle; 2024 Apr; 15(2):631-645. PubMed ID: 38333911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
